<DOC>
	<DOC>NCT02491047</DOC>
	<brief_summary>This is a prospective, multi-national, multicenter, randomized, two arms, single blind, Standard of Care (SOC) controlled, with blinded central reading center study. This study will assess the safety and performance of BonyPid-1000™ in severe open tibial fractures (Gustilo IIIA and IIIB) when implanted as adjunct to SOC and compared to SOC alone.</brief_summary>
	<brief_title>Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Tibial Fractures</mesh_term>
	<mesh_term>Fractures, Open</mesh_term>
	<criteria>1. Male or nonpregnant female with age ≥ 18 years and ≤70 years. 2. Subjects with tibia open fractures of Gustilo grade, IIIA or IIIB 3. Multiinjured subjects who are hemodynamically and physiologically stable 4. Subjects who are able and willing to sign an informed consent form, prior to any protocolspecific procedures being performed and accept to comply with protocol requirements for the duration of the study. 1. Female who is pregnant or breastfeeding. 2. Subjects with known current disseminated malignancies, active cancer or autoimmune diseases. 3. Subjects with fractures due to known medical history of Osteoporosis. 4. Diabetic subjects who are drug or insulin dependent. 5. Heavy smokers in the last 6 months. 6. Nonambulating subjects prior to the trauma. 7. Subjects admitted to Emergency Room (ER) more than 24 hours (&gt; 24h) post injury. 8. Subjects with bone fracture due to known medical history of metabolic bone diseases. 9. Subjects with hypersensitivity to doxycycline and or tetracycline family of drugs. 10. Subjects treated with systemic doxycycline during the last 4 weeks prior to screening. 11. Previous surgical intervention in the target fracture site. 12. Subjects currently receiving or have received an investigational product in the last 30 days and/or participate in another clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>